MedTrace Logo

Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

NCT00518245 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-01-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether enoxaparin (an anticoagulant) is effective in the treatment of patients presenting to the emergency room with chest pain and no electrocardiogram or bloodwork evidence of a heart attack, but with other high risk clinical features

Conditions

  • Unstable Angina

Interventions

DRUG

enoxaparin

Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Canadian Heart Research Centre

    lead OTHER

Principal Investigators

  • Shaun Goodman, MD, MSc · Canadian Heart Research Centre

  • David Fitchett, MD · Unity Health Toronto

  • Anatoly Langer, MD, MSc · Canadian Heart Research Centre

  • Andrew T Yan, MD · Canadian Heart Research Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-03-31
Completion
2009-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518245 on ClinicalTrials.gov